How metformin may help protect lungs in tuberculosis patients
Lung-Protective Mechanisms of Metformin in TB
This study is looking at whether metformin, a diabetes medication, can help boost the immune system in people with tuberculosis (TB) to reduce lung damage and fight the infection better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-10767263 on NIH RePORTER |
What this research studies
This research investigates the potential of metformin, a medication commonly used for diabetes, to enhance the body's natural defenses against tuberculosis (TB). The study focuses on understanding how metformin can reduce lung damage and bacterial load in TB patients by harnessing the body's immune response. Researchers will explore the specific immune mechanisms involved, particularly how metformin influences certain immune cells that help fight TB and promote lung repair. By analyzing data from previous patients treated with metformin, the study aims to provide insights into its effectiveness as a host-directed therapy for TB.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with tuberculosis or at risk of developing it.
Not a fit: Patients who do not have tuberculosis or are not at risk for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for tuberculosis, potentially reducing lung damage and enhancing recovery in patients.
How similar studies have performed: Previous studies have shown promising results with metformin in reducing TB infection rates and improving outcomes, suggesting that this approach may be effective.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Kornfeld, Hardy — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Kornfeld, Hardy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.